This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutEfficacy & SafetyDosingDosingInitiating NGENLADosing & StorageDevice DemonstrationOrdering InformationSupport & ResourcesSupport & ResourcesStarter Kits
 
Endocrine HelplineHomecare
 
Formulary PackShared Care Guide TemplateContact UsNICE RecommendationNgenla Patient Case StudiesFormulary Pack
MaterialsVideosMeetings & Events
My Ngenla PlanMy Ngenla PlanMy Ngenla PlanMy Ngenla Plan Overview 

Prescribing Information for NGENLA(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.

NGENLA is recommended by NICENGENLA is recommended as an option for treating growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over1.

What this means for your service

NGENLA was recommended through a cost comparison approach and the NHS agreed to provide funding to implement this guidance within 30 days of publication in England and 60 days in Wales.1,2,3

NGENLA should have been made available for use on the 3rd March in England and 2nd April in Wales, for use in appropriate patients.1

Pfizer is here to support you with the implementation of this guidance, please follow the links below for support resources:

NICE Cost Comparison Approach​​

A cost comparison method is used by NICE if a health technology is likely to provide similar health benefits at a similar cost than medicines recommended in a published NICE technology appraisal guidance for the same indication.4

To read more about the NICE recommendation for NGENLA, click here.

NGENLA is competitively priced to support uptake of innovation in the UK​​​​

The NHS list price of NGENLA is £6.92/mg equivalent to an estimated annual cost of £7,125 for a 30kg patient.

Yearly cost of treatment for a 30kg pGHD patient using NHS list prices5†


† Please note, this graph does not compare the clinical efficacy of the products mentioned. All costs calculated assume that patients will take their medicine as prescribed- every day for 365 days a year for daily growth hormone and every week for 52 weeks for NGENLA.
The cost/mg values that have been used for each brand are5: Saizen: £23.18, Norditropin: £22.22
, Nutropin AQ: £20.30, Humatrope: £18.00, Genotropin: £17.39, Zomacton: £17.07, and Biosimilar Omnitrope: £14.75
Please note as Norditropin has a price range of £21.27-£23.18, an average price of £22.22 has been used. 


NGENLA may deliver a treatment experience favoured by patients and caregivers​​​​​

NGENLA delivered a favoured treatment experience for patients and caregivers in a phase 3 crossover study versus daily Genotropin (somatropin) in pGHD, demonstrating a lower treatment burden and higher intention to comply.6,7

For safety & efficacy data click here.

Study Design  
Patients and caregivers (N=87) reported improved (lower) Life Interference total score after 12 weeks of once-weekly NGENLA treatment compared to once-daily GH.6,7 Phase 3, randomised, open-label, 2-period, crossover, multicentre study assessing patient perception of treatment burden with the use of NGENLA once weekly versus Genotropin once daily in children 3 to <18 years of age with GH deficiency.6,7

Data are based on patient/caregiver recall following each 12-week treatment period and at the end of the study. Caregivers completed the assessment for children under 8 years of age.6,7
† Based on Patient Global Impression Severity-Impact on Daily Activities.7

Scroll left to view table
Explore more

The NGENLA team are here to support you with any queries. Find out how you can get in touch.

Contact Us Loading

Learn more about the Homecare services available to support NGENLA patients.

Homecare  Loading

References:

NICE- Somatrogon for treating growth disturbance in children and young people aged 3 and over. Available at: https://www.nice.org.uk/guidance/ta863 [Accessed on 26 June 2023]NICE- Achieving and demonstrating compliance with NICE TA and HST guidance. Available at: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/achieving-and-demonstrating-compliance [Accessed on 26 June 2023]NICE- National Institute for Health and Care Excellence (NICE) Guidelines. Available at: https://www.gov.wales/national-institute-health-and-care-excellence-nice-guidelines [Accessed on 26 June 2023]NICE. Cost comparison: methods addendum. Available at: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/methods-guide-addendum-cost-comparison.pdf [Accessed on 26 June 2023]BNF database (somatropin). Accessed via Medicines Complete. https://about.medicinescomplete.com/. Accessed June 2023.NGENLA Summary of Product Characteristics for Great Britain: https://www.medicines.org.uk/emc/search?q=ngenla & Northern Ireland: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=4319e9d0-5396-4363-8dcb-bc72051b39da&type=smpcManiatis AK, et al. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study. J Endocr Soc. 2022, 6, 1–10.
PP-NGE-GBR-0459. June 2023

Access data on the efficacy and safety profile of NGENLA.

Efficacy & Safety 

Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​